When should Monofer (iron isomaltoside/ferric derisomaltose) be used instead of Venofer (iron sucrose) in hospitalized patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Use Monofer versus Venofer in Hospital

Monofer (ferric derisomaltose) should be preferred over Venofer (iron sucrose) in hospitalized patients when rapid, complete iron repletion is needed in a single visit, as Monofer allows up to 1000-2000 mg administration in 20-30 minutes versus Venofer's maximum of 200-500 mg requiring multiple visits. 1, 2, 3

Key Decision Algorithm

Choose Monofer when:

  • Single-dose complete repletion is desired: Monofer can deliver 1000 mg (or up to 20 mg/kg, max 1500-2000 mg) in one 20-30 minute infusion 1, 2
  • Minimizing hospital visits/infusions: Particularly important for inpatient efficiency and patient convenience
  • Patients weighing ≥50 kg: Standard 1000 mg single dose 2
  • Patients weighing <50 kg: Dose as 20 mg/kg actual body weight 2
  • Cardiovascular benefit matters: Monofer is the first IV iron showing statistically significant reduction in cardiovascular death in heart failure patients 1

Choose Venofer when:

  • Hemodialysis patients requiring maintenance dosing: Venofer 100 mg per dialysis session is FDA-approved and well-established 3
  • Pediatric patients ≥2 years: Venofer has specific pediatric dosing (0.5 mg/kg, max 100 mg) 3
  • Lower single doses preferred: Maximum 200-500 mg per infusion depending on indication 3
  • Cost constraints exist: Venofer is typically less expensive, though requires multiple visits 4

Administration Differences

Monofer Dosing:

  • Adults ≥50 kg: 1000 mg IV over ≥20 minutes 2
  • Adults <50 kg: 20 mg/kg IV over ≥20 minutes 2
  • Dilute in 100-500 mL normal saline (concentration >1 mg/mL) 2
  • Single total dose infusion capability 1

Venofer Dosing:

  • HDD-CKD: 100 mg per dialysis session over 2-5 minutes or 15 minutes (total course 1000 mg) 3
  • NDD-CKD: 200 mg × 5 doses over 14 days 3
  • PDD-CKD: 300 mg × 2, then 400 mg over 28 days 3
  • Requires multiple visits to achieve total iron repletion 1

Safety Considerations

Both formulations have comparable safety profiles 1, 5, 6:

  • Hypersensitivity reactions: Similar rates (Monofer 0.3%, Venofer comparable) 1, 5
  • Anaphylaxis: Extremely rare with both (<0.1%) 1
  • Hypophosphatemia: Less common with Monofer compared to ferric carboxymaltose; not a significant concern with Venofer 1, 7
  • Cardiovascular events: Monofer showed significantly lower composite cardiovascular adverse events versus Venofer in CKD patients (4.1% vs 6.9%, P=0.025) 5

Critical Safety Requirements for Both:

  • Monitor patients for ≥30 minutes post-infusion 2, 3
  • Have resuscitation equipment immediately available 2, 3
  • Monitor for extravasation (can cause long-lasting brown discoloration) 2

Efficacy Comparison

Meta-analyses show no significant difference in hemoglobin response between Monofer and Venofer 6, 8:

  • Hemoglobin change at week 4: No difference (MD 0.09 g/dL) 6
  • Hemoglobin change at week 8: No difference (MD 0.04 g/dL) 6
  • However, Monofer produces faster ferritin rise at week 2 (P=0.02) 5, 8

Clinical Populations

Both are effective in:

  • Non-dialysis CKD 1, 5
  • Inflammatory bowel disease 1
  • Heart failure with iron deficiency 1
  • Pregnancy 1, 9

Venofer has specific advantage in:

  • Hemodialysis maintenance therapy: Established dosing protocol, FDA-approved for pediatrics 3, 10

Practical Hospital Considerations

Monofer is superior for inpatient efficiency:

  • Single infusion completes therapy (versus 5-10 visits with Venofer) 1
  • Shorter total infusion time for complete repletion
  • Reduces nursing time and IV access complications
  • Better for patients with difficult IV access

Common Pitfall: Do not check iron parameters within 4 weeks of total dose infusion—circulating iron interferes with assays 1

Monitoring: Check CBC and iron parameters (ferritin, TSAT) at 4-8 weeks post-infusion for both formulations 1

References

Research

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2021

Research

Intravenous Ferric Derisomaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anemia in Pregnancy: A Randomized, Comparative Trial.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2026

Research

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.